Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease

Ikuko Hirai, Keiji Tanese, Yoshio Nakamura, Maki Ishii, Yutaka Kawakami, Takeru Funakoshi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. Although several chemotherapies have been tried, the effects are temporary; better drugs and combinations are required. In the present study, we retrospectively analyze the efficacy and safety of combination of cisplatin, epirubicin, and paclitaxel in five metastatic EMPD cases. The efficacy was better than that for previously reported regimens: 80% partial responses, including two patients who were refractory to taxane- and/or platinum-based regimens. In terms of safety, four patients who were able to continue treatment exhibited acceptable tolerability. This is the first regimen to combine taxane and anthracycline. When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, and anthracycline in combination with taxane constitutes a key chemotherapeutic regimen. Given our results, we speculate both drugs are critical chemotherapeutic agents for the treatment of metastatic EMPD.

Original languageEnglish
JournalOncologist
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Extramammary Paget's Disease
Epirubicin
Anthracyclines
Breast Neoplasms
Cytotoxins
Drug Combinations
Therapeutics
Patient Safety
Platinum
Adenocarcinoma
Safety
Drug Therapy
Skin
TP protocol
Pharmaceutical Preparations
taxane

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease. / Hirai, Ikuko; Tanese, Keiji; Nakamura, Yoshio; Ishii, Maki; Kawakami, Yutaka; Funakoshi, Takeru.

In: Oncologist, 01.01.2019.

Research output: Contribution to journalArticle

@article{89bcfbcdeb004620b115acd3dfec5b08,
title = "Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease",
abstract = "Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. Although several chemotherapies have been tried, the effects are temporary; better drugs and combinations are required. In the present study, we retrospectively analyze the efficacy and safety of combination of cisplatin, epirubicin, and paclitaxel in five metastatic EMPD cases. The efficacy was better than that for previously reported regimens: 80{\%} partial responses, including two patients who were refractory to taxane- and/or platinum-based regimens. In terms of safety, four patients who were able to continue treatment exhibited acceptable tolerability. This is the first regimen to combine taxane and anthracycline. When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, and anthracycline in combination with taxane constitutes a key chemotherapeutic regimen. Given our results, we speculate both drugs are critical chemotherapeutic agents for the treatment of metastatic EMPD.",
author = "Ikuko Hirai and Keiji Tanese and Yoshio Nakamura and Maki Ishii and Yutaka Kawakami and Takeru Funakoshi",
year = "2019",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2018-0856",
language = "English",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease

AU - Hirai, Ikuko

AU - Tanese, Keiji

AU - Nakamura, Yoshio

AU - Ishii, Maki

AU - Kawakami, Yutaka

AU - Funakoshi, Takeru

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. Although several chemotherapies have been tried, the effects are temporary; better drugs and combinations are required. In the present study, we retrospectively analyze the efficacy and safety of combination of cisplatin, epirubicin, and paclitaxel in five metastatic EMPD cases. The efficacy was better than that for previously reported regimens: 80% partial responses, including two patients who were refractory to taxane- and/or platinum-based regimens. In terms of safety, four patients who were able to continue treatment exhibited acceptable tolerability. This is the first regimen to combine taxane and anthracycline. When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, and anthracycline in combination with taxane constitutes a key chemotherapeutic regimen. Given our results, we speculate both drugs are critical chemotherapeutic agents for the treatment of metastatic EMPD.

AB - Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. Although several chemotherapies have been tried, the effects are temporary; better drugs and combinations are required. In the present study, we retrospectively analyze the efficacy and safety of combination of cisplatin, epirubicin, and paclitaxel in five metastatic EMPD cases. The efficacy was better than that for previously reported regimens: 80% partial responses, including two patients who were refractory to taxane- and/or platinum-based regimens. In terms of safety, four patients who were able to continue treatment exhibited acceptable tolerability. This is the first regimen to combine taxane and anthracycline. When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, and anthracycline in combination with taxane constitutes a key chemotherapeutic regimen. Given our results, we speculate both drugs are critical chemotherapeutic agents for the treatment of metastatic EMPD.

UR - http://www.scopus.com/inward/record.url?scp=85062708062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062708062&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2018-0856

DO - 10.1634/theoncologist.2018-0856

M3 - Article

C2 - 30846514

AN - SCOPUS:85062708062

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -